PMID- 19934608
OWN - NLM
STAT- MEDLINE
DCOM- 20100126
LR  - 20220316
IS  - 1598-9992 (Print)
IS  - 1598-9992 (Linking)
VI  - 54
IP  - 5
DP  - 2009 Nov
TI  - [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
PG  - 269-78
AB  - Eleven years has passed since the guideline of the Korean College of Helicobacter 
      and Upper Gastrointestinal Research group for H. pylori infection was produced in 
      1998. During this period the research for H. pylori has much progressed that H. 
      pylori is now regarded as the major cause of gastric cancer. The seroprevalence 
      of H. pylori in Korea was found to be decreased especially below the age of 40s 
      and in the area of Seoul-Gyeonggi province, and annual reinfection rate of H. 
      pylori has decreased up to 2.94%. In the aspect of diagnostic tests of H. pylori 
      the biopsy is recommended in the body instead of antrum in the subjects with 
      atrophic gastritis and/or intestinal metaplasia for the modified Giemsa staining 
      or Warthin Starry silver staining. The urea breath test is the test of choice to 
      confirm eradication when follow-up endoscopy is not necessary. Definite 
      indication for H. pylori eradication is early gastric cancer in addition to the 
      previous indications of peptic ulcer including scar and Marginal zone B cell 
      lymphoma (MALT type). Treatment is also recommended for the relatives of gastric 
      cancer patient, unexplained iron deficiency anemia, and chronic idiopathic 
      thrombocytopenic purpura. One or two week treatment of proton pump inhibitor 
      (PPI) based triple therapy consisting of one PPI and two antibiotics, 
      clarithromycin and amoxicillin, is recommended as the first line treatment 
      regimen. In the case of treatment failure, one or two weeks of quadruple therapy 
      (PPI+metronidazole+tetracycline+bismuth) is recommended. Herein, Korean College 
      of Helicobacter and Upper Gastrointestinal Research proposes a diagnostic and 
      treatment guideline based on currently available evidence.
FAU - Kim, Nayoung
AU  - Kim N
AD  - Department of Internal Medicine, Seoul National University College of Medicine, 
      Seoul National University Bundang Hospital, Seongnam, Seoul, Korea.
FAU - Kim, Jae J
AU  - Kim JJ
FAU - Choe, Yon Ho
AU  - Choe YH
FAU - Kim, Hyun Soo
AU  - Kim HS
FAU - Kim, Jin Il
AU  - Kim JI
FAU - Chung, In-Sik
AU  - Chung IS
CN  - Korean College of Helicobacter and Upper Gastrointestinal Research
CN  - Korean Association of Gastroenterology
LA  - kor
PT  - Journal Article
PT  - Practice Guideline
PL  - Korea (South)
TA  - Korean J Gastroenterol
JT  - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
JID - 101189416
RN  - 0 (Antacids)
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - F8VB5M810T (Tetracycline)
RN  - H1250JIK0A (Clarithromycin)
RN  - U015TT5I8H (Bismuth)
SB  - IM
MH  - Amoxicillin/therapeutic use
MH  - Antacids/therapeutic use
MH  - Anti-Infective Agents/therapeutic use
MH  - Bismuth/therapeutic use
MH  - Breath Tests
MH  - Clarithromycin/therapeutic use
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Gastroscopy
MH  - Helicobacter Infections/*diagnosis/*drug therapy
MH  - *Helicobacter pylori
MH  - Humans
MH  - Metronidazole/therapeutic use
MH  - Peptic Ulcer/diagnosis
MH  - Proton Pump Inhibitors/therapeutic use
MH  - Stomach Neoplasms/diagnosis
MH  - Tetracycline/therapeutic use
EDAT- 2009/11/26 06:00
MHDA- 2010/01/27 06:00
CRDT- 2009/11/26 06:00
PHST- 2009/11/26 06:00 [entrez]
PHST- 2009/11/26 06:00 [pubmed]
PHST- 2010/01/27 06:00 [medline]
AID - 200911252 [pii]
AID - 10.4166/kjg.2009.54.5.269 [doi]
PST - ppublish
SO  - Korean J Gastroenterol. 2009 Nov;54(5):269-78. doi: 10.4166/kjg.2009.54.5.269.